Valley NewsCompany
· 3w
The official news channel of Valley
OMass Therapeutics Raises €275 Million Series C for Small-Molecule Pipeline
Oxford spin-out OMass Therapeutics has closed an oversubscribed €275 million (£230 million) Series C round to advance its small-molecule therapies, which target highly validated target ecosystems. The round was co-led by new investors Bain Capital Life Sciences, Forbion and Novo Holdings. Janus Henderson Investors, SV Health Investors and Jefferson Life Sciences also participated.
Key takeaway: A €275 million oversubscribed round led by three new institutional backers signals that specialist life sciences capital remains available at scale for late-stage European biotech with differentiated discovery platforms.
Source: EU-Startups
Biotech #Funding #VC
🔗 https://www.eu-startups.com/2026/10/o...
0
2